DBV Technologies surges on Phase 3 trial win for peanut allergy therapy
Source: SeekingAlpha
2025-12-17 06:56:09 ET
More on DBV Technologies
- DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript
- DBV Technologies: Uncertainty Still Exists Despite Recent 90% Rally
- DBV Technologies announces $30 million ADS sale
- DBV Technologies announces $30 million ADS sale
- Seeking Alpha’s Quant Rating on DBV Technologies
Read the full article on Seeking Alpha
For further details see:
DBV Technologies surges on Phase 3 trial win for peanut allergy therapy
DBV Technologies S.A.
NASDAQ: DBVT
DBVT Trading
-3.69% G/L:
$20.71 Last:
174,244 Volume:
$22.02 Open:
DBVT Latest News
February 28, 2026 02:25:00 pm
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
February 10, 2026 04:30:00 pm
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
February 09, 2026 04:30:00 pm
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
February 05, 2026 04:30:00 pm
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
DBVT Stock Data
$801,767,672
33,335,677
74.36%
21
N/A
Biotechnology & Life Sciences
Healthcare
FR
Chtillon
